skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8129

Characteristics of respondents with glaucoma and dry eye in a national panel survey

Original Research

(2422) Views  (912) Full article downloads

Authors: Jordana K Schmier, David W Covert

Published Date November 2009 Volume 2009:3 Pages 645 - 650
DOI: http://dx.doi.org/10.2147/OPTH.S8241

Jordana K Schmier1, David W Covert2

1Exponent Inc., Alexandria, VA, USA; 2Alcon Research, Ltd., Fort Worth, TX, USA

Background: There is an increasing body of evidence strongly suggesting that glaucoma medications may contribute to ocular surface disease and development of dry eye.

Objective: To identify glaucoma patients with dry eye, using a nationally representative sample, and to compare clinical and treatment characteristics with controls without dry eye.

Methods: Patients taking intraocular pressure-lowering medications were identified from the Medical Expenditure Panel Survey. A matched cohort without glaucoma served as controls. Dry eye was identified by diagnosis or use of prescription or over-the-counter medications. Demographic and clinical characteristics and medication use patterns were compared.

Results: The analysis identified 629 respondents with glaucoma and 6,934 controls without glaucoma. Dry eye was more common among glaucoma respondents than nonglaucoma controls (16.5% vs 5.6%, P < 0.0001). There was a nonsignificant trend for respondents with dry eye to report higher rates of glaucoma adjunctive therapy use compared to those without dry eye (44.2% vs 35.0%, P < 0.076). Prostaglandin analogs were the most common glaucoma medication.

Conclusions: This analysis found that the rate of dry eye was higher in patients with glaucoma than in controls. The use of glaucoma adjunctive therapies may increase the rate of dry eye in glaucoma patients.

Keywords: dry eye syndromes, health care surveys, glaucoma






 

Other articles by Ms J K Schmier

First-year treatment costs among new initiators of topical prostaglandin analogs
First-year treatment costs among new initiators of topical prostaglandin analogs: pooled results
Two-year treatment patterns and costs in glaucoma patients initiating treatment with prostaglandin analogs